Navigation Links
Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy
Date:4/3/2011

y the European Medicines Agency (the "EMA") based on the pixantrone (PIX 301) phase III study results.  

For more information on the PIX-R trial, investigators and patients can visit www.pixrtrial.com, and www.clinicaltrials.gov.

About Pixantrone

Pixantrone is a novel aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents. Similar to anthracyclines, pixantrone inhibits Topo-isomerase II but unlike anthracyclines--rather than intercalation with DNA--pixantrone alkylates DNA--forming stable DNA adducts, with particular specificity for CpG rich, hyper-methylated sites. These structural differences resulted in significantly enhanced anti-lymphoma activity compared to doxorubicin in preclinical models. In addition, the structural motifs on anthracycline-like agents that are responsible for the generation of oxygen free radicals and the formation of toxic drug-metal complexes have also been modified in pixantrone to prevent the binding of iron and perpetuation of superoxide production--both of which are the putative mechanism for anthracycline induced acute cardiotoxicity. These novel pharmacologic differences may allow re-introduction of anthracycline like potency in the treatment of relapsed/refractory aggressive lymphoma without unacceptable rates of cardiotoxicity.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert<
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDAs Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone
2. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
3. European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
4. Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 10, 2010
5. Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
6. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
7. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
8. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
9. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
10. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
11. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... Mass. and SYDNEY , May ... - ASX: HIN), a leading innovator of less invasive, ... advanced heart failure, today announced that CEO Doug ... UBS Global Healthcare Conference at 11:00 a.m. EDT on Monday, ... 2013 at the Sheraton New York Hotel. A ...
(Date:5/16/2013)... May 16, 2013 AcelRx Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapies for the treatment of ... King , President and CEO, will present a corporate ... New York Hotel in New York , ... at 9:30 a.m. ET/6:30 a.m. PT. The presentation ...
(Date:5/16/2013)... -- Developers of a pill bottle that wirelessly transmits data, ... prize winners in the Healthcare Innovation World Cup , ... organized by HITLAB . Winning team members ... and Mike Morena of ... will receive $50,000 in prize money. They earned ...
Breaking Medicine Technology:HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast 2AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference 2AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference 3Wireless Pill Bottle Wins Healthcare Innovation World Cup 2Wireless Pill Bottle Wins Healthcare Innovation World Cup 3Wireless Pill Bottle Wins Healthcare Innovation World Cup 4Wireless Pill Bottle Wins Healthcare Innovation World Cup 5
... 2011 MediSapiens Ltd , a Finnish ... gene expression yet for public use. The data is available ... home page of MediSapiens Ltd , allowing exploration of ... healthy human tissues. Since the sequencing of the human genome, ...
... SAN CARLOS, Calif. and SAN DIEGO, Sept. 29, 2011 ... maternal and fetal health, today announced it has signed ... developer and manufacturer of life sciences tools for the ... Under the terms of the agreement, Verinata Health will ...
Cached Medicine Technology:Transcriptome Viewer - Comprehensive Genome-wide Map of Human Gene Expression Activity Released for Public by MediSapiens 2Verinata Health Announces a Multi-Year Supply Agreement with Illumina in the Field of Non-Invasive Prenatal Diagnostics 2
(Date:5/18/2013)... (May 18, 2013) A ground-breaking advance in ... according to research presented today at Digestive Disease ... minimal withdrawal time for colonoscopies and exploring safer ... colonoscopy, doctors use a device called a colonoscope ... colorectal cancer allows a doctor to look for ...
(Date:5/18/2013)... May 18, 2013 The “World Healthcare ... and studies the major market drivers, restraints, and opportunities ... world. , Browse , 89 ... in-depth TOC on "Healthcare IT Market" , ... customization on reports. , The global healthcare IT market ...
(Date:5/18/2013)... May 18, 2013 During Better Hearing ... should consider the legal protections they have, including the ... arise with their child’s treatment or hearing aid device, ... 1927, the American Speech-Language-Hearing Association has used the month ... to promote treatment, such as cochlear implants, which can ...
(Date:5/18/2013)... Adolescents, especially young males, who experiment with synthetic ... landing in emergency rooms across America. Recovery ... with a new treatment program for those addicted to ... the National Institute on Drug Abuse, synthetic marijuana has ... In 2012, 11 percent of high school seniors had ...
(Date:5/18/2013)... 2013 The American Society for ... Kitzhaber, M.D., (D) to sign a bill (HB 2896) ... under the age of 18 from tanning indoors. , ... state in the nation to enact an under-18 tanning ... tanning bans for minors. Nationwide, 34 states and the ...
Breaking Medicine News(10 mins):Health News:New colonoscope provides ground-breaking view of colon 2Health News:New colonoscope provides ground-breaking view of colon 3Health News:New colonoscope provides ground-breaking view of colon 4Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 2Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 3Health News:Spice Addiction Treatment and Synthetic Marijuana Drug Rehab Announced by Recovery Associates 2Health News:ASDSA Urges Oregon Governor to Sign Under-18 Indoor Tanning Restrictions 2
... live but weakened versions of the H5N1 bird flu virus ... the solution to to stockpile vaccines ahead of a pandemic. ... underway, and this could lead to the start of a ... ,The researchers wrote in the online journal ...
... the largest number of polio cases. According to a senior ... abroad are spreading the disease. ,"Investigation of strains ... in the African countries of Congo and Mozambique has revealed ... Polio Coordinator for Uttar Pradesh. ,Nearly, 280 cases ...
... is natural for a patient to tread carefully, fearing ... overriding emotions// after a heart attack, which cannot be ... occasion to allay the doubts and uncertainties that ebb ... ,Often, ambiguous communication from caregivers cause more harm than ...
... fined American Red Cross a record $4.2 million for ... other safety problems//. ,The Food and Drug Administration ... in previous fines since 2003, calling attention to a ... Cross is a humanitarian organization which depends heavily on ...
... PLC, a company that manufactures a lot of skincare products, ... killing the H5N1 bird flu virus in 30 seconds.// ... Retroscreen Virology Ltd, a European contract Virology research company for ... Solutions Limited ('DDS'). ,It also said that the ...
... Nicole's drastic weight loss that he agreed to take her to ... to contactmusic.com, Richie was scared for his daughter's health and wanted ... ,He says: "Believe me, I've checked it out three different ways ... said, 'Okay, what is it?' Is it really an eating disorder?' ...
Cached Medicine News:Health News:Vaccine Made from Live bird flu virus vaccine Offers Protection to Animals 2Health News:American Red Cross Fined $4.2m for Improper Blood Screening 2
... Spot Vital Signs device ... seconds. The basic unit ... pulse rate and mean ... Vital Signs additional parameters ...
... CS offers the features needed for quality, ... 8.4-inch TFT color display allows you to ... vectors of ECG. The touch screen allows ... impaired by gloves or temperature., ,Standard ...
... The Acuity LT Central Monitoring Station ... self-contained and ready to go right out ... patient surveillance in specific care areas rather ... the ICU. As patient-to-caregiver ratios continue to ...
... the smallest handheld oximeters available, Datex-Ohmeda s ... hospital, home care, transport, and EMS. TuffSat ... ,PIr (relative perfusion index measurement) a ... numeric reflection of perfusion at the sensor ...
Medicine Products: